Advancing AAV Manufacturing: TESSA^® Platform for Scalable and Efficient Gene Therapy Production

TESSA^®️ vectors are self-silencing E1/E3 deleted Ad5 vectors, genetically engineered to cripple its own replication cycle, and delivery ‘Ad helper functions and AAV Rep/Cap genes into serum-free suspension HEK293 cells for scalable AAV manufacture.

TESSA^®️ Duo – co-infection with two TESSA^®️ vectors (RepCap & GOI) yields over 30 times more AAV compared to the triple transfection process. Scaling up production in bioreactors yields of >7E+11 GC per mL of cell culture and >1E+17 GC of rAAV6.

TESSA^®️ Pro – co-infection using rAAV and TESSA^®️ RepCap enables >5,000-fold amplification of input rAAV, yielding up to 4E+11 – 2E+12 GC/mL. TESSA^®️ Pro process exhibits high efficiency in genome packaging, generating up to 90% full capsids before purification.

TESSA^®️ technology integrates in-house testing capabilities, including biosafety assessments, viral clearance, and product release testing.